# US 2019/0169285 A1 · Anti-IL31 Antibodies for Veterinary Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169285 A1
- Document ID: US20190169285A1
- Status: Published application
- Kind: A1
- Application number: 16/186,013
- Filed: 2018-11-09
- Published: 2019-06-06
- Earliest claimed: 2017-02-24
- Assignees: Kindred Biosciences, Inc.
- Applicants: Kindred Biosciences, Inc.
- Inventors: Shyr Jiann Li; Lam Nguyen; Hangjun Zhan
- Web page: https://patentgrep.com/patent/US20190169285A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61K 2039/552: {Veterinary vaccine}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

## Claims

### Claim at position 1

-29. (canceled)

### Claim 30

A method of treating a companion animal species having an IL31-induced condition, the method comprising administering to the companion animal species a therapeutically effective amount of an isolated antibody that binds to an epitope of canine IL31 comprising the amino acid sequence of SEQ ID NO: 23.

### Claim 31 (depends on 30)

The method of claim 30, wherein the companion animal species is canine or feline.

### Claim 32 (depends on 30)

The method of claim 30, wherein the IL31-induced condition is a pruritic or allergic condition.

### Claim 33 (depends on 30)

The method of claim 30, wherein the IL31-induced condition is selected from atopic dermatitis, pruritus, asthma, psoriasis, scleroderma and eczema.

### Claim 34 (depends on 30)

The method of claim 30, wherein the antibody is administered parenterally.

### Claim 35 (depends on 30)

The method of claim 30, wherein the antibody is administered by an intramuscular route, an intraperitoneal route, an intracerebrospinal route, a subcutaneous route, an intra-arterial route, an intrasynovial route, an intrathecal route, or an inhalation route.

### Claim 36 (depends on 30)

The method of claim 30, wherein the method comprises administering in combination with the antibody a Jak inhibitor, a PI3K inhibitor, an AKT inhibitor, or a MAPK inhibitor.

### Claim 37 (depends on 30)

The method of claim 30, wherein the method comprises administering in combination with the antibody one or more antibodies selected from an anti-IL17 antibody, an anti-TNFα antibody, an anti-CD20 antibody, an anti-CD19 antibody, an anti-CD25 antibody, an anti-IL4 antibody, an anti-IL13 antibody, an anti-IL23 antibody, an anti-IgE antibody, an anti-CD11α antibody, anti-IL6R antibody, anti-α4-Intergrin antibody, an anti-IL12 antibody, an anti-IL1β antibody, and an anti-BlyS antibody.

### Claim at position 10

-45. (canceled)

### Claim 46 (depends on 30)

The method of claim 30, wherein the antibody binds to canine IL31 with a dissociation constant (Kd) of less than 5×10−11 M, as measured by biolayer interferometry.

### Claim 47 (depends on 30)

The method of claim 30, wherein the antibody binds to canine IL31 with a dissociation constant (Kd) of less than 1×10−11 M, as measured by biolayer interferometry.

### Claim 48 (depends on 30)

The method of claim 30, wherein the antibody reduces IL31 signaling function in a canine or feline cell, as measured by a reduction in STAT-3 phosphorylation.

### Claim 49 (depends on 30)

The method of claim 30, wherein the antibody binds to feline IL31, as determined by immunoblot analysis or biolayer interferometry.

### Claim 50 (depends on 30)

The method of claim 30, wherein the antibody competes with monoclonal M14 antibody in binding to canine IL31.

### Claim 51 (depends on 30)

The method of claim 30, wherein the antibody competes with monoclonal M14 antibody in binding to feline IL31.

### Claim 52 (depends on 30)

The method of claim 30, wherein the antibody comprises:
(a) a variable light chain sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24 and a variable heavy chain sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25; or
(b) a variable light chain sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 16 and a variable heavy chain sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 15.